HSP's 1Q11 IMS Sales Are Improving, Morgan Stanley Reports

1Q11 IMS sales are improving for Hospira Inc. HSP, Morgan Stanley reports. “On a reported basis, total Hospira IMS sales were down 4% y/y QTD 1Q11m,” Morgan Stanley writes. “However, sales were up 23% y/y and 16% vs 4Q10 (excluding oxaliplatin) with recent launches (Zosyn and gemcitabine) accounting for ~50% of growth y/y. “The overall generic injectable market is up 8% and 32% y/y excluding oxaliplatin and enoxaparin. Hospira's overall market share increased to 29% QTD vs 25% in 4Q10.” Hospira closed Thursday at $55.20.